Author

Yuki Makino

The University of Texas MD Anderson Cancer CenterORCID 0000-0002-2690-4548Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Yuki Makino1 paper · The University of Osaka

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

Anirban MaitraiD· 3 shared Fredrik I. ThegeiD· 2 shared Kimal RajapaksheiD· 2 shared Akiko SagaraiD· 1 shared Amber Hoskins· 1 shared Andrew J. GundersoniD· 1 shared Angela R.S. KruseiD· 1 shared Annaliese Kramer· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Anirban MaitraORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 4, 2026

Targeting AXL Overcomes Adaptive Resistance to KRAS Inhibition in KRAS-Driven Cancer

Fredrik I. Thege, Annaliese Kramer, Norbert Kreisz…·Anirban Maitra

This study identifies AXL as a driver of adaptive resistance to KRAS inhibition and shows that combining AXL and KRAS inhibition improves tumor control and immune response in lung and pancreatic cancer models.

1 citation

mousegenetic perturbation / CRISPR

Cancer BiologyGutPeer-reviewedSep 13, 2024

Metabolic Reprogramming by Mutant GNAS Creates an Actionable Dependency in Intraductal Papillary Mucinous Neoplasms of the Pancreas

Yuki Makino, Kimal Rajapakshe, Benson Chellakkan Selvanesan…·Fredrik I. Thege

This study shows that mutant GNAS drives a gastric metaplasia gene signature and glycolytic dependency in IPMNs, offering a therapeutic target.

16 citations

mousebulk RNA-seq

Cancer BiologybioRxivPreprintFeb 25, 2024

Mutant GNAS drives a pyloric metaplasia with tumor suppressive glycans in intraductal papillary mucinous neoplasia

Vincent Quoc‐Huy Trinh, Katherine E. Ankenbauer, Sabrina M. Torbit…·Kathleen E. DelGiorno

This study identifies GNASR201C as a driver of pyloric metaplasia in IPMN, characterized by tumor-suppressive glycans that inhibit cancer progression.

5 citations

humanbulk RNA-seq